Credit Suisse raised the firm’s price target on Bio-Rad to $680 from $640 and keeps an Outperform rating on the shares. The Q4 miss is more than compensated by the solid business outlook, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIO:
- Bio-Rad reports Q4 EPS $3.31, consensus $3.45
- Bio-Rad and Element Biosciences announce partnership
- Cytek Biosciences partners with Bio-Rad to expand reagent portfolios
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
- Early notable gainers among liquid option names on January 26th
